Methylphenidate Adverse Events Will Be Topic Of Pediatric Advisory Committee In June
This article was originally published in The Pink Sheet Daily
Executive Summary
As required by the Best Pharmaceuticals for Children Act, the advisory committee will review adverse event reports for Johnson & Johnson's Concerta and other methylphenidate products on June 30. Reports for other drugs will be considered June 29.
You may also be interested in...
J&J Concerta Psychiatric Adverse Event Labeling Change Proposed By FDA
Post-marketing adverse event reports spur the labeling change for Concerta and other methylphenidate ADHD therapies. The agency is also examining adverse event reports for amphetamine ADHD therapies and Lilly's Strattera to determine if there is a similar risk.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).